



# Essai Clinique

Généré le 18 mai 2025 à partir de

Titre	Spatially Fractionated Radiation (SFR) Therapy as Palliative Radiation for Patients With Advanced and Symptomatic Tumors
Protocole ID	GRID
ClinicalTrials.gov ID	<a href="https://clinicaltrials.gov/ct2/show/study/NCT02333110">NCT02333110</a>
Type(s) de cancer	Tumeurs solides
Stade	Maladie avancée ou métastatique
Type étude	Support
Institution	CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS 3755 rue de la Côte Ste. Catherine, Montréal, QC, H3T 1E2
Ville	Montréal
Investigateur principal	Dre Té Vuong
Coordonnateur	Harielle Lamarre 514-340-8222 poste 26199
Statut	Actif en recrutement
But étude	Palliative radiation therapy represents 40% of the on-going radiation at the Jewish General Hospital. In a traditional palliative radiation treatment to bulky or radioresistant tumors, radiotherapy schema varies from 24 to 30 Gys given in 3 to 10 fractions, depending on the tumor size, tumor location and tumor pathology. However, for many patients this treatment involves considerable toxicity, travel and time spent at the hospital. Spatially fractionated radiation (SFR) is an alternative technique that consists in delivering one single treatment, given through a grid containing holes. The present study is proposing to validate SFR as a safe and effective mean to palliate patients with symptomatic bulky tumors (more than 8 cm) or with tumors known to be resistant to radiation.
Critères d'éligibilité	<ul style="list-style-type: none"><li>• Patient with histologically or cytologically confirmed malignancy. All malignant histologies/cytologies are eligible.</li><li>• Patient with bulky tumor (larger than 8cm), or with a tumor known to be resistant to radiation (eg. Melanoma, hypernephroma, sarcoma), or with a tumor previously irradiated with a palliative intent requiring more than 1 fraction of radiation</li><li>• Patient planned to undergo palliative radiation therapy treatments to one of the following 5 sites: extremities, neck, chest, abdomen and pelvis</li><li>• WHO performance status of 0-2</li><li>• Aged 18 years or older</li><li>• Ability to sign and understand an informed consent form</li></ul>
Critères d'exclusion	<ul style="list-style-type: none"><li>• Potentially curable patient</li><li>• Previous palliative radiation with hypofractionation</li><li>• Tumor located near the spinal cord or in the brain</li><li>• Pregnant or nursing woman</li></ul>